Mounjaro Before Surgery: What Your Anaesthetist Needs to Know

If you are taking Mounjaro before surgery, there are important steps you need to follow to reduce your anaesthetic risk. Tirzepatide slows gastric emptying, which means food can remain in your stomach longer than expected. For your anaesthetist, this raises the possibility of pulmonary aspiration during general anaesthesia or deep sedation.

However, the guidance has evolved significantly since 2023. Most patients do not need to stop Mounjaro entirely before an elective procedure. In this guide, we explain the current clinical recommendations, who is at higher risk, and exactly what you should discuss with your surgical team.

In most cases, no. The 2024 multi-society guidance from the American Society of Anesthesiologists (ASA), the American Gastroenterological Association, and three other surgical and perioperative bodies states that most patients can continue taking their GLP-1 receptor agonist before elective surgery. The earlier 2023 ASA recommendation to hold weekly injections for seven days before a procedure has been replaced by a more nuanced, risk-stratified approach.

Patients who are experiencing active gastrointestinal side effects, who are in a dose-escalation phase, or who have a history of gastroparesis may need additional precautions. For these higher-risk patients, a liquid-only diet for 24 hours before the procedure is the primary recommendation.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. One of its therapeutic effects is slowing gastric emptying, which contributes to appetite reduction and improved blood glucose control. This is beneficial for weight management, but it creates a specific concern during anaesthesia.

When you undergo general anaesthesia, your protective airway reflexes are suppressed. If there is undigested food or liquid in your stomach at the point of intubation, there is a risk of gastric contents entering your lungs. This is known as pulmonary aspiration, and although it is rare, it can cause serious complications including aspiration pneumonitis and, in severe cases, respiratory failure.

The MHRA Summary of Product Characteristics (SmPC) for Mounjaro specifically notes this concern in Section 4.4, stating that the increased risk of residual gastric content due to delayed gastric emptying should be considered prior to performing procedures with general anaesthesia or deep sedation. Importantly, standard preoperative fasting protocols (typically six hours for solids, two hours for clear fluids) may not be sufficient to guarantee an empty stomach in all patients taking tirzepatide.

It is worth noting that tirzepatide does not directly interact with anaesthetic drugs themselves. The concern is purely mechanical: the speed at which your stomach empties its contents.

The 2024 multi-society clinical practice guidance, published jointly by the ASA, AGA, ASMBS, ISPCOP, and SAGES, represents the most comprehensive perioperative framework for GLP-1 receptor agonists to date. Furthermore, the British Journal of Anaesthesia has published a Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement addressing the same issues for UK practice.

The key recommendations are as follows. For most patients on a stable dose without active GI symptoms, continuing Mounjaro as prescribed is acceptable. For higher-risk patients (those during dose escalation, those with active nausea, vomiting, bloating, or a history of gastroparesis), a 24-hour liquid-only diet before the procedure is recommended. Additionally, point-of-care gastric ultrasound immediately before induction can be used to assess residual stomach volume in patients at highest risk. If significant gastric contents are found on ultrasound, the anaesthetic team may choose to delay the procedure, use rapid-sequence induction, or modify the anaesthetic technique.

This is a substantial shift from the 2023 ASA guidance, which broadly recommended holding weekly GLP-1 injections for seven days before surgery. The updated consensus acknowledges that the risk of aspiration is generally low for patients on stable doses and that the metabolic and glycaemic benefits of continuing treatment often outweigh the risks of temporary discontinuation.

Not all patients on Mounjaro carry the same perioperative risk. Your anaesthetist will assess your individual circumstances, but generally the following factors increase the likelihood of delayed gastric emptying at the time of surgery:

Dose escalation. The early weeks of treatment, or the period following a dose increase, are when GI side effects are most pronounced. Gastric emptying is typically slowest during these phases. If you have recently moved to a higher dose of tirzepatide, your surgical team will likely recommend extra precautions.

Active GI symptoms. If you are currently experiencing nausea, vomiting, bloating, or acid reflux on Mounjaro, these symptoms suggest that gastric motility is still significantly reduced. In these patients, the anaesthetist may want additional reassurance that the stomach is empty before proceeding.

Pre-existing gastroparesis. Patients with diabetic gastroparesis or other causes of impaired gastric motility are already at baseline risk. Adding tirzepatide compounds this further. In particular, these patients may require extended fasting periods or prokinetic medication before surgery.

Higher doses. Research suggests that higher doses of GLP-1 receptor agonists produce greater delays in gastric emptying. Patients on 10 mg or 15 mg of tirzepatide may be at relatively higher risk compared with those on 2.5 mg or 5 mg maintenance doses.

Transparency is essential. At your pre-operative assessment, you should inform your surgical team of the following details. First, confirm that you are taking tirzepatide (Mounjaro), including the exact dose and how long you have been on it. Second, mention when your last injection was, as the timing relative to surgery is relevant. Third, describe any current GI symptoms such as nausea, bloating, reflux, or constipation. Fourth, note whether you have recently had a dose increase and how long ago it occurred.

It is also important to mention if you are taking any oral medications with a narrow therapeutic index, such as warfarin. The MHRA SmPC notes that tirzepatide can alter the absorption rate of co-administered oral medicines, and your surgical team may need to check levels or adjust timing around the procedure.

In addition, do not assume that your GP records will automatically reach the anaesthetic team. Many patients receive Mounjaro through private weight-management clinics, and these prescriptions may not appear in NHS hospital records. Bring your prescription details or a recent clinic letter with you.

Elective surgery allows time for preparation, but emergencies do not. If you need emergency surgery while taking Mounjaro, the anaesthetic team will treat you as a patient with a potentially full stomach regardless of when you last ate. This means rapid-sequence induction (RSI) with cricoid pressure will almost certainly be used.

Consequently, it is helpful to carry information about your Mounjaro prescription with you, particularly if you travel. A medical alert card or a note in your phone listing the medication name, dose, and prescriber contact can save valuable time in an emergency setting. Your CutKilo clinic team can provide a letter confirming your treatment details if you request one.

After your procedure, the timing for restarting tirzepatide depends on the type of surgery and how quickly you recover normal oral intake. For minor day-case procedures under local or regional anaesthesia, you can generally continue your usual injection schedule without interruption.

For procedures involving general anaesthesia, particularly abdominal or gastrointestinal surgery, your surgeon may advise waiting until you are tolerating solid food comfortably before resuming injections. Similarly, if you paused Mounjaro before the operation, your prescriber may recommend restarting at a lower dose to reduce the chance of post-operative nausea overlapping with the GI side effects of re-initiation.

At CutKilo, we advise patients to contact us before and after any planned procedure so we can adjust the dosing schedule appropriately. Your weight-loss progress will not be significantly affected by a short pause around surgery.

Can I have Mounjaro before a colonoscopy or endoscopy? Yes, but the same principles apply. These procedures typically require sedation rather than full general anaesthesia, which carries a lower aspiration risk. Nevertheless, your gastroenterologist may ask you to follow an extended clear-liquid diet or to time your last injection further from the procedure date. Always disclose your tirzepatide use when booking the appointment.

Does Mounjaro affect local anaesthesia? No. Tirzepatide does not interact with local anaesthetic agents. If your procedure uses only local or regional anaesthesia (for example, dental surgery, skin excisions, or joint injections), there is no need to change your Mounjaro schedule. The concern about gastric emptying is specific to general anaesthesia and deep sedation, where airway reflexes are suppressed.

How long does Mounjaro delay gastric emptying? Clinical data from the SURMOUNT programme shows that tirzepatide slows gastric emptying most significantly in the first few weeks of treatment and during dose escalation. After approximately 12 weeks at a stable dose, gastric emptying rates tend to normalise or near-normalise in most patients. This is why patients on stable long-term doses are generally considered lower risk.

Will my surgery be cancelled if I am on Mounjaro? It should not be. The current multi-society guidance explicitly states that GLP-1 receptor agonist use alone is not a reason to cancel or postpone elective surgery. If your anaesthetist has concerns, they will typically modify the anaesthetic plan (for example, using point-of-care gastric ultrasound or rapid-sequence induction) rather than cancelling the procedure outright.

Should I fast longer than normal before surgery if I take Mounjaro? For most patients on a stable dose without GI symptoms, standard fasting times (six hours for solids, two hours for clear fluids) are likely adequate. For higher-risk patients, the guidance recommends a 24-hour liquid-only diet. Your pre-operative assessment team will advise you based on your individual circumstances.

Taking Mounjaro before surgery is safe for most patients, provided your anaesthetic team knows about it. The 2024 multi-society consensus has moved away from blanket recommendations to stop GLP-1 medications before elective procedures. Instead, the emphasis is on individual risk assessment, clear communication with your surgical team, and targeted precautions for patients who are at higher risk of delayed gastric emptying.

If you have a planned procedure coming up, let your CutKilo prescriber know as early as possible. We can help you coordinate the timing of your injections and provide a clinic letter for your surgical team. Above all, do not stop Mounjaro abruptly without medical advice, as this can affect both your blood glucose control and your weight-management progress.